0000000000276034

AUTHOR

Uli Luxemburger

showing 3 related works from this author

Enhanced production of CCL18 by tolerogenic dendritic cells is associated with inhibition of allergic airway reactivity

2012

Background IL-10–treated dendritic cells (DCs) have been shown to inhibit T-cell responses through induction of anergy and regulatory T cells in various model systems, including allergic inflammation, but the factors being involved in this inhibition are still unclear. Objective This study set out to analyze such factors produced or induced by IL-10–treated DCs by using gene expression profiling and to explore their function. Methods CD4 + T cells from allergic donors were stimulated with autologous monocyte-derived allergen-pulsed mature DCs or IL-10–treated DCs. After 24 hours, the transcriptional profile was analyzed by using Affymetrix technology. Results were validated by using quantit…

CD4-Positive T-LymphocytesChemokinemedicine.medical_treatmentImmunologyT-Lymphocytes RegulatoryAllergic inflammationMiceMice Inbred NODImmune ToleranceRespiratory HypersensitivitymedicineAnimalsHumansImmunology and AllergyCCL17dendritic cellsCells CulturedT(H)1/T(H)2 cellsMice KnockoutbiologyCCL18FOXP3regulationDendritic cellMicroarray AnalysisallergyCoculture TechniquesInterleukin-10Disease Models Animalhumanized miceCytokineChemokines CCImmunologyHumanized mousebiology.proteinChemokinesTranscriptomeJournal of Allergy and Clinical Immunology
researchProduct

Abstract CT202: IVAC MUTANOME: Individualized vaccines for the treatment of cancer

2015

Abstract Cancer arises from the accumulation of genomic alterations and epigenetic changes that constitute a hallmark of cancer. Owing to the molecular heterogeneity in cancer, only a minor fraction of patients profit from approved therapies. Available targeted therapies can only address alterations common to a particular type of cancer and induce transient effects due to the generation of resistant sub-clones. In contrast, the IVAC MUTANOME project aims to immunologically target multiple cancer mutations uniquely expressed in a given patient's tumor. The IVAC MUTANOME approach should be applicable to the majority of patients irrespective of the tumor entity and offers the potential to expl…

PrioritizationGerontologyOncologyCancer Researchmedicine.medical_specialtybusiness.industryMelanomaCancermedicine.diseaseMolecular heterogeneityPhase i studyClinical trialOncologyTolerabilityInternal medicinemedicinebusinessExomeCancer Research
researchProduct

CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein

2004

A multitude of antigens has been recently identified by screening of cDNA expression libraries derived from human tumors with autologous sera. Using a phage autoantibody assay and small panels of sera derived from cancer patients or controls it has been shown that some of these antigens display cancer-associated autoantibody responses. The diagnostic and prognostic significance of these potentially cancer-related autoantibodies remains unclear until large-scale assays are developed and serological data are available for hundreds of cancer patients and controls. The major bottleneck for the development of large-scale assays are the cloning, expression and the purification of each of the resp…

Antibodies NeoplasmImmunologyEnzyme-Linked Immunosorbent AssayBiologyAutoantigensSerologylaw.inventionAntigenAntigens NeoplasmlawEscherichia colimedicineHumansImmunology and AllergyAutoantibodiesCloningchemistry.chemical_classificationAutoantibodyMembrane ProteinsCancermedicine.diseaseVirologyMolecular biologyRecombinant ProteinsTumor antigenEnzymechemistryRecombinant DNAJournal of Immunological Methods
researchProduct